文章：

低剂量纳曲酮作为联合抗癌治疗的辅助药物

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy

原文发布日期：21 March 2024

DOI: 10.3390/cancers16061240

类型: Article

开放获取: 是

英文摘要：

Naltrexone (NTX) is a non-selective antagonist of opioid receptors, primarily used in the therapy of opioid and alcohol dependence. Low-dose naltrexone (LDN) exhibits antagonistic action against the opioid growth factor receptor (OGFr), whose signaling is associated with the survival, proliferation, and invasion of cancer cells. The mechanism of action of LDN depends on the dose and duration of the OGFr blockade, leading to a compensatory increase in the synthesis of the opioid growth factor (OGF), which has an inhibitory effect on carcinogenesis. Numerous studies on in vitro and in vivo models provide evidence of LDN’s positive impact on inhibiting the OGF–OGFr axis in cancers. LDN’s unique mechanism of action on cancer cells, lack of direct cytotoxic effect, and immunomodulating action form the basis for its use as an adjuvant in chemotherapy and immunotherapy of cancerous lesions.

摘要翻译： 

纳曲酮（NTX）是一种非选择性阿片受体拮抗剂，主要用于治疗阿片类药物和酒精依赖。低剂量纳曲酮（LDN）对阿片生长因子受体（OGFr）具有拮抗作用，该受体的信号传导与癌细胞的存活、增殖和侵袭相关。LDN的作用机制取决于OGFr阻断的剂量和持续时间，导致阿片生长因子（OGF）的合成代偿性增加，从而对致癌过程产生抑制作用。大量体外和体内模型研究证实，LDN对癌症中OGF–OGFr轴具有积极的抑制作用。LDN对癌细胞独特的作用机制、缺乏直接细胞毒性作用以及免疫调节作用，为其作为癌症病变化疗和免疫治疗的辅助用药奠定了基础。

原文链接：

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy